LAG3 deficiency enhance Th1 cells and decrease Treg upon adoptive transfer into wild-type mice followed by <i>E</i>. <i>multilocularis</i> infection. by Dewei Li (2806207)

Map showing study region (southern shores of Lake Victoria, Tanzania). by Roland Proud (11764892)

Localization of the size-modified HMW2 derivatives in the attachment organelle. by Daisuke Nakane (833480)

Length and distance of the attachment organelle and speed of gliding motility in the size-modified HMW2-derivative mutants. by Daisuke Nakane (833480)

DataSheet_1_NOTCH1 mutation associates with impaired immune response and decreased relapse-free survival in patients with resected T1-2N0 laryngeal cancer.zip by Xiao-yang Gong (13103400)

“…Due to the small number of patients in this study, these differences need to be further validated in a larger cohort.</p>…”

Effects of single gene RNAi knockdown experiments. by Michael A. Najarro (831657)

Clone size distributions for all child patients. by John M. Murray (150672)

Both oral arginine and citrulline protect against eCM. by Irene Gramaglia (6439613)

Clone size distributions at years 0.2, 4.8 and 11.4 years after the commencement of ART for Patient 1 of Maldarelli et al. by John M. Murray (150672)

NPY neuron-specific Y2 deletion in the hypothalamus increases NPY and decreases POMC expression in the arcuate nucleus with no significant effects on body weight, spontaneous or fa... by Yan-Chuan Shi (153820)

Poly I:C increased HIF-1α and NF-κB which induced miR-210 leading to decreased STAT6 and IL-4 in human CTBs. by Shelley E. Kopriva (313874)

Demographic data of patients with POAG and OHT. by Chareenun Chirapapaisan (8843843)

“…In total, 28 eyes were included in the study, with a mean patient age of 65.71±10.2 years. After IOP reduction, all biometric parameters, except CCT and ACD, exhibited a decrease without reaching statistical significance (all p>0.05). …”

Participant and lab results flow. by Gad Murenzi (6243719)

“…</p><p>Results</p><p>Women included in this analysis (N = 4,880) had a mean age of 40 years, > 98% were on antiretroviral therapy, and 61% had a CD4 count of ≥500 cells/µL. …”

Illustration of the main differences in ulna morphology between running groups, based on morphometric and microarchitecture analyses. by Andy Xavier (20141395)

Agent model of latency. by John M. Murray (150672)

Raw data. by Wei Li (7081)

“…The purpose of this study was to assess the cost-effectiveness of sugemalimab vs. placebo for consolidation treatment of stage III NSCLC from the perspective of the Chinese healthcare system.</p><p>Methods</p><p>A 3-state Markov model with a 3-week cycle length was performed to appraise the incremental cost-utility ratio (ICUR) of sugemalimab consolidation therapy based on the GEMSTONE-301 clinical trial over a 10-year time horizon. …”

Best fit and the values of the parameters. by Wei Li (7081)

“…The purpose of this study was to assess the cost-effectiveness of sugemalimab vs. placebo for consolidation treatment of stage III NSCLC from the perspective of the Chinese healthcare system.</p><p>Methods</p><p>A 3-state Markov model with a 3-week cycle length was performed to appraise the incremental cost-utility ratio (ICUR) of sugemalimab consolidation therapy based on the GEMSTONE-301 clinical trial over a 10-year time horizon. …”

Base-case analysis results without or with PAP. by Wei Li (7081)

“…The purpose of this study was to assess the cost-effectiveness of sugemalimab vs. placebo for consolidation treatment of stage III NSCLC from the perspective of the Chinese healthcare system.</p><p>Methods</p><p>A 3-state Markov model with a 3-week cycle length was performed to appraise the incremental cost-utility ratio (ICUR) of sugemalimab consolidation therapy based on the GEMSTONE-301 clinical trial over a 10-year time horizon. …”

Results of scenario analyses for cCRT population. by Wei Li (7081)

“…The purpose of this study was to assess the cost-effectiveness of sugemalimab vs. placebo for consolidation treatment of stage III NSCLC from the perspective of the Chinese healthcare system.</p><p>Methods</p><p>A 3-state Markov model with a 3-week cycle length was performed to appraise the incremental cost-utility ratio (ICUR) of sugemalimab consolidation therapy based on the GEMSTONE-301 clinical trial over a 10-year time horizon. …”

Live-cell imaging reveals multiple patterns of Tax expression in naturally-infected T-cell clones. by Saumya Ramanayake (7879091)